RSV vaccine side effects: adults, babies, and pregnancy
Most adults get a sore arm for a day or two, and how likely that is depends on which product they were given. Injection site pain was reported by 60.9% of AREXVY recipients, 55.9% of MRESVIA recipients and 10.6% of ABRYSVO recipients aged 60 and older, each measured against its own placebo group (each product’s US prescribing information). Median duration was 1 to 2 days.
Babies do not receive an RSV vaccine at all, and there is a section on that below. Every rate here names its product, its denominator and its label, and sits beside the placebo arm from the same trial.
The three adult RSV vaccines are not interchangeable
Search results treat “the RSV vaccine” as one thing. Three are licensed in the United States for adults, and they are built differently.
- AREXVY (GSK): 120 mcg of a recombinant RSV prefusion F protein plus the AS01E adjuvant, an ingredient added to strengthen the immune response.
- ABRYSVO (Pfizer): 120 mcg of two recombinant prefusion F proteins, one for RSV A and one for RSV B, with no adjuvant.
- MRESVIA (Moderna): 50 mcg of nucleoside-modified mRNA in a lipid nanoparticle, which instructs your own cells to make the prefusion F protein.
AREXVY and ABRYSVO are built from a manufactured piece of the virus rather than from the virus itself. None of the three contains live RSV.
Each label warns that rates from one vaccine’s trials cannot be compared directly with another’s, and the diaries differ: a 4-day paper card for AREXVY, 7-day electronic diaries for the other two. Read each column below against its own placebo arm.
How common each side effect is, by product
These figures are for adults 60 years of age and older, the group all three products are licensed for.
| Reaction | AREXVY | AREXVY placebo | ABRYSVO | ABRYSVO placebo | MRESVIA | MRESVIA placebo |
|---|---|---|---|---|---|---|
| Participants with diary data | 879 | 874 to 878 | 3,628 | 3,447 | 18,146 to 18,156 | 18,092 to 18,094 |
| Injection site pain, any | 60.9% | 9.3% | 10.6% | 6.1% | 55.9% | 13.8% |
| Injection site pain, severe | 1% | 0% | under 0.1% | 0% | 1.7% | 1.1% |
| Redness | 7.5% | 0.8% | 2.7% | 0.6% | 2.0% | 0.6% |
| Swelling | 5.5% | 0.6% | 2.5% | 0.4% | 3.7% | 0.3% |
| Fatigue | 33.6% | 16.1% | 15.7% | 14.8% | 30.8% | 20.0% |
| Muscle pain | 28.9% | 8.2% | 10.2% | 8.5% | 25.6% | 14.4% |
| Headache | 27.2% | 12.6% | 12.9% | 12.0% | 26.7% | 18.8% |
| Joint pain | 18.1% | 6.4% | 7.6% | 7.0% | 21.7% | 14.0% |
| Fever, at least 38 C (100.4 F) | 2.0% | 0.3% | 1.4% | 1.5% | 2.7% | 1.3% |
Sources: AREXVY Prescribing Information Table 2 (Study 1, 4-day card), ABRYSVO Prescribing Information Tables 4 and 5 (Study 3, 7-day e-diary), MRESVIA Prescribing Information Tables 2 and 3 (Study 1, 7-day e-diary). Redness and swelling were counted above 20 mm for AREXVY and at 1 inch or more for the other two. The MRESVIA diary solicited two reactions the others did not: underarm swelling or tenderness, 15.2% against 6.1%, and chills, 11.6% against 6.8%.
The spread in the top row is the finding. Injection site pain after ABRYSVO was reported by about one person in ten, and after AREXVY by about six in ten. Both are recombinant protein vaccines, and the visible difference is that AREXVY carries an adjuvant. The labels do not attribute the gap to any single ingredient, and the trials were run separately, so treat it as a pattern rather than a proven cause.
Now read the placebo columns. In the AREXVY trial, 12.6% of people given salt water reported a headache and 16.1% reported fatigue. In the MRESVIA trial, 20.0% of placebo recipients reported fatigue. Those symptoms do not stop happening because someone had a vaccine, and setting a reported reaction against the rate expected anyway is the basis of vaccine safety monitoring. ABRYSVO fever was 1.4% against 1.5% on placebo, level or below. Redness and swelling run several times the placebo rate in all three trials, so a red and puffy arm really is the injection.
Younger adults report more, not less. Among AREXVY recipients aged 50 through 59, injection site pain was 75.8% against 12.1% on placebo and fatigue 39.8% against 18.2% (756 vaccine recipients versus 379 placebo recipients, AREXVY Prescribing Information Table 3). MRESVIA reported injection site pain in 73.9% of 502 participants aged 18 through 59, in a study with no placebo arm.
How long RSV vaccine side effects last
Days, not weeks. Each label publishes a median.
- AREXVY: local reactions a median of 2 days and systemic reactions 1 to 2 days in adults 60 and older; 2 to 3 days and 1 to 2 days in adults 50 through 59.
- ABRYSVO: local and systemic reactions a median of 1 to 2 days in adults 60 and older.
- MRESVIA: local and systemic reactions a median of 1 to 2 days in adults 60 and older; a median onset of 2.0 days and a median duration of 3 days in adults 18 through 59.
A median means half of people resolved faster and half took longer. None of the labels publishes the length of the tail.
One number gets quoted out of context. In the full AREXVY trial, unsolicited adverse events within 30 days were reported by 33.0% of 12,467 vaccine recipients and 17.8% of 12,499 placebo recipients. That is a reporting window, not a duration, and the label attributes the gap mainly to events matching the solicited reactions above.
RSV vaccine side effects in pregnancy
Only ABRYSVO is licensed for use in pregnancy, and only at 32 through 36 weeks gestational age. The AREXVY label states it is not for use in pregnant individuals, and the MRESVIA label read for this article carries no pregnancy indication.
In the main maternal trial, 3,698 pregnant participants received ABRYSVO and 3,687 received placebo, with reactions recorded in a 7-day electronic diary.
| Reaction within 7 days | ABRYSVO | Placebo |
|---|---|---|
| Participants with diary data | 3,663 | 3,638 to 3,639 |
| Injection site pain, any | 40.6% | 10.1% |
| Redness | 7.2% | 0.2% |
| Swelling | 6.2% | 0.2% |
| Fatigue | 46.1% | 43.8% |
| Headache | 31.0% | 27.6% |
| Muscle pain | 26.5% | 17.1% |
| Nausea | 20.0% | 19.2% |
| Joint pain | 11.6% | 10.5% |
| Diarrhea | 11.2% | 11.5% |
| Vomiting | 7.8% | 7.0% |
| Fever, at least 38 C (100.4 F) | 2.6% | 2.9% |
Source: ABRYSVO Prescribing Information Tables 1 and 2, Study 1 (NCT04424316).
The arm reactions separate cleanly: 40.6% against 10.1% for pain, with redness and swelling at more than 30 times the placebo rate. The whole-body symptoms mostly do not. Fatigue was 46.1% against 43.8%, nausea 20.0% against 19.2%, diarrhea 11.2% against 11.5%, and fever was lower after the vaccine than after placebo, 2.6% against 2.9%.
Read plainly, most of what a pregnant person feels that week is the pregnancy, not the vaccine. Muscle pain, 26.5% against 17.1%, is the one whole-body symptom with a clear gap. Severe systemic reactions were reported by 2.3% of both groups, and most reactions resolved within 2 to 3 days of onset.
Why the 32 to 36 week window exists
The label discusses a numerical imbalance in preterm births. In Study 1, preterm birth occurred in 5.7% of the ABRYSVO group (207 of 3,659, 95% CI 4.9 to 6.5) and 4.7% of the placebo group (172 of 3,646, 95% CI 4.1 to 5.5). In the smaller Study 2 it was 5.3% (6 of 114) against 2.6% (3 of 116).
The label states: “Available data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO.” It then gives the reason for the dosing window: “To avoid the potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer ABRYSVO as indicated in pregnant individuals at 32 through 36 weeks gestational age.”
Among participants vaccinated inside that window, preterm birth was 4.3% (71 of 1,667) against 3.7% (60 of 1,640). The gap is narrower inside the licensed window than across the whole trial. Two limits belong with those figures. Pregnant individuals at increased risk of preterm birth were generally excluded from the studies, and ABRYSVO has not been studied before 24 weeks gestational age.
Maternal serious adverse events at any point in the study were 16.6% against 15.8%, most of them pregnancy complications arising more than a month after the injection. Pre-eclampsia was 1.8% against 1.4%. The label also points to a pregnancy exposure registry on 1-800-616-3791. Our course pages cover vaccination during pregnancy in general terms, and your national immunization guidance takes precedence over anything here.
RSV vaccine side effects in babies
There is no RSV vaccine for babies. If you searched that phrase, the product you have in mind is one of two things, and neither is a vaccine given to an infant.
The first is maternal vaccination. ABRYSVO goes to the pregnant parent and antibodies cross the placenta, so the infant receives antibodies rather than a vaccine. In the maternal trial, adverse events in infants from birth to 1 month were reported for 38.0% of the ABRYSVO group and 35.4% of the placebo group, out of 3,659 and 3,646 infants. Low birth weight was 5.1% against 4.3% and neonatal jaundice 7.3% against 6.9%, while congenital malformations or anomalies were lower after the vaccine, 5.6% (205 infants) against 6.7% (245 infants).
The second is nirsevimab, sold as BEYFORTUS. It is a human IgG1 monoclonal antibody directed at the RSV fusion protein. It supplies ready-made antibody by injection, so it is a medicine rather than a vaccine, and it does not prompt the infant to make antibodies of its own. It is given as a single weight-based intramuscular dose for a first RSV season, 50 mg for babies under 11 pounds and 100 mg for babies 11 pounds or more.
Its reaction rates are low. In the pooled safety population of two placebo-controlled trials, 2,570 infants received the recommended dose and 1,284 received placebo, all followed for 360 days. Adverse reactions were reported in 1.2% of infants given nirsevimab, and 97% of those were mild to moderate. Two were reported more often than on placebo: rash within 14 days in 0.9% against 0.6%, and injection site reactions within 7 days in 0.3% against 0% (BEYFORTUS Prescribing Information Table 3).
Its label carries two warnings worth knowing. Serious hypersensitivity reactions have been reported after nirsevimab, including hives, difficulty breathing, blue discoloration of the skin and floppiness. It should also be given with caution to infants with a low platelet count, any clotting disorder, or on anticoagulant treatment.
What counts as a severe reaction
“Severe” in these labels is a functional threshold, not an emergency. Across all four products it means a reaction that prevents normal daily activity. AREXVY and MRESVIA call it Grade 3, and for MRESVIA the pain definition also covers any use of a prescription pain reliever.
Severe injection site pain was reported by 1% of AREXVY recipients aged 60 and older, 3.4% of those aged 50 through 59, 1.7% of MRESVIA recipients against 1.1% on placebo, and under 0.1% of ABRYSVO recipients. Severe fatigue was 1.7% after AREXVY against 0.5% on placebo, and 1.7% after MRESVIA against 1.2%.
Someone meeting that definition canceled their day. That is not a medical emergency, and our course material sets out the difference between expected reactions and severe ones.
Guillain-Barre syndrome and other rare events
Guillain-Barre syndrome is the rare event these labels discuss at the greatest length. Two of the three address it with figures. The third does not mention it.
AREXVY. A postmarketing study of Medicare beneficiaries 65 and older, covering May 2023 through July 2024, compared a risk window of 1 to 42 days after vaccination against a control window of 43 to 90 days. It found an incidence rate ratio of 2.46 (95% CI 1.19, 5.08) and an estimated 7 excess cases of Guillain-Barre syndrome per million doses given to people 65 and older. The label adds that available evidence is insufficient to establish a causal relationship.
ABRYSVO. The same study design gave an incidence rate ratio of 2.02 (95% CI 0.93, 4.40) and an estimated 9 excess cases per million doses in people 65 and older, with the same causality caveat. That confidence interval includes 1, so this analysis on its own does not rule out no effect.
MRESVIA. The prescribing information read for this article, revised 8/2026, carries no Guillain-Barre warning and no postmarketing experience section. It gives no rate, so none is quoted here.
Both labels add that the excess case estimate depends on the background rate of Guillain-Barre syndrome in the study population, so these two figures should not be lined up against estimates from other vaccines.
For scale, serious adverse events sat level with placebo in every trial: 4.2% against 4.0% for AREXVY within 6 months (12,467 and 12,499 participants), 6.2% against 6.1% for ABRYSVO, and 7.8% against 7.9% for MRESVIA. AREXVY deaths at a median 12.2 months of follow-up were 0.9% in each arm, and potential immune-mediated diseases within 6 months were 0.3% in each arm.
Three ABRYSVO serious events were assessed as possibly related: Guillain-Barre syndrome at 7 days, later revised to chronic inflammatory demyelinating polyneuropathy, Miller Fisher syndrome at 8 days, and a hypersensitivity reaction at 8 hours. One MRESVIA participant had facial paralysis 4 days after vaccination, assessed as related, with no imbalance at 28 or 42 days. Both the AREXVY and ABRYSVO trials also flagged an imbalance in atrial fibrillation within 30 days, 10 cases against 4 and 11 against 3, and both labels state that available information is insufficient to determine a causal relationship.
When to get medical help
A severe allergic reaction starts soon after the injection. Get emergency care for difficulty breathing, swelling of the face or throat, hives, a racing heart or sudden faintness. All four labels list a history of a severe allergic reaction, such as anaphylaxis, to the product or any component as a contraindication.
Call your clinician, without rushing, for anything outside the pattern in the tables above:
- A reaction still getting worse on day 4 or later
- Redness or swelling that keeps spreading
- Pain that stops you doing normal daily things
- New weakness, tingling or difficulty walking in the weeks after an adult dose
- Any symptom not listed on the label
Tell whoever gives the injection if you have fainted after one before. Fainting can happen with any injectable vaccine, and all three adult labels carry that precaution. This site publishes reference information and does not give medical advice.
How to report a reaction, and where the report goes
Report it even if you are not sure the product caused it. Where the report goes depends on which product was given, and each label prints the route on its front page.
The three adult vaccines route to the Vaccine Adverse Event Reporting System (VAERS) on 1-800-822-7967 or vaers.hhs.gov, alongside the manufacturer’s own line. Nirsevimab does not. Because it is a monoclonal antibody rather than a vaccine, its label directs suspected adverse reactions to Sanofi on 1-855-239-3678, or to the FDA on 1-800-FDA-1088 or www.fda.gov/medwatch.
VAERS states its own purpose this way: “VAERS is not designed to determine if a vaccine caused a health problem, but is especially useful for detecting unusual or unexpected patterns of adverse event reporting that might indicate a possible safety problem with a vaccine” (vaers.hhs.gov). It is co-managed by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), and anyone can report to it. Other countries run their own systems, and national guidance takes precedence.
The Guillain-Barre wording on two of these labels exists because of that process. The trials, at 24,966 participants for AREXVY and 36,862 for ABRYSVO in adults 60 and older, did not produce it. Postmarketing surveillance did. Deciding whether a product caused an event is a separate, formal exercise and not the reporter’s job. Our course covers how vaccine safety monitoring works and how adverse events are classified.
FAQ
How long do RSV vaccine side effects last?
One to three days for most people. The AREXVY label gives a median of 2 days for local reactions and 1 to 2 days for systemic ones in adults 60 and older. ABRYSVO and MRESVIA both give a median of 1 to 2 days in that age group, and MRESVIA gives a median of 3 days in adults 18 through 59. Half of people resolved sooner than the median.
What are the RSV vaccine side effects in babies?
Babies do not get an RSV vaccine. Infant protection comes either from antibodies passed on after the pregnant parent receives ABRYSVO, or from nirsevimab (BEYFORTUS), a monoclonal antibody given by injection. In the nirsevimab trials, 2,570 infants got the recommended dose and 1,284 got placebo. Rash within 14 days was reported in 0.9% against 0.6%, and injection site reactions within 7 days in 0.3% against 0%.
Which RSV vaccine has the fewest side effects?
On its own trial numbers, ABRYSVO reported the lowest rates in adults 60 and older: injection site pain in 10.6% against 6.1% on placebo, compared with 60.9% for AREXVY and 55.9% for MRESVIA. Every label states that rates from different trials cannot be compared directly, and reactogenicity is only one input into which product you are offered. That decision follows national immunization guidance, not this page.
Can the RSV vaccine give me RSV?
No. None of the three adult vaccines contains live RSV. AREXVY and ABRYSVO contain a manufactured copy of one virus protein, and MRESVIA contains mRNA that instructs your cells to make that protein. There is no whole virus in any of them to cause an infection.
Is a strong reaction a sign the vaccine is working?
The labels read for this article report no link between how strongly you react and how well you are protected. They do show that the adjuvanted product produced more reactions than the unadjuvanted one, and that adults under 60 reported more reactions than adults 60 and older. Treat a rough 48 hours as a rough 48 hours.
Do I need an RSV vaccine every year?
The labels read for this article describe a single dose and state no revaccination interval, so this page has nothing to add on repeat dosing. Follow your national immunization guidance.
Side effects of other vaccines
We publish the same kind of rate table for other vaccines, taken from the manufacturer’s prescribing information and shown beside the placebo group from the same trial.
- Shingles vaccine side effects covers Shingrix by age band, how long reactions last, and whether the second dose is worse than the first.
- Pneumonia vaccine side effects covers Pneumovax 23, Prevnar 20 and Capvaxive day by day, including what a reaction after one week means.
